4-bromo-5-hydroxysulfamoyl-N-(2-(morpholin-4-yl)ethyl)thiophene-2-carboxamide | 1135370-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 4-bromo-5-hydroxysulfamoyl-N-(2-(morpholin-4-yl)ethyl)thiophene-2-carboxamide
• 英文别名: 4-bromo-5-(hydroxysulfamoyl)-N-(2-morpholin-4-ylethyl)thiophene-2-carboxamide
• CAS: 1135370-59-0
• 化学式: C₁₁H₁₆BrN₃O₅S₂
• 分子量: 414.301
• InChiKey: QAHKWQNPFDIXML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  145
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• [EN] N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS<br/>[FR] DÉRIVÉS DE N-HYDROXYLSULFONAMIDE UTILISÉS COMME NOUVEAUX DONNEURS DE NITROXYLE PHYSIOLOGIQUEMENT UTILES
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2009042970A1

  公开（公告）日：2009-04-02

  The invention relates to N-hydroxylsulfonamide derivatives for formula (I), (II) or (III), in which the variables are as defined in the claims, that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. N-hydroxylsulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of the functional groups on the N-hydroxylsulfonamide derivatives.

  该发明涉及公式（I）、（II）或（III）的N-羟基磺酰胺衍生物，其中变量如索权中定义的那样，在生理条件下释放亚硝基（HNO），并且在治疗和/或预防对亚硝基疗法敏感的疾病或病症的发生和/或发展中具有用处，包括心力衰竭和缺血/再灌注损伤。N-羟基磺酰胺衍生物在生理条件下以受控速率释放HNO，HNO释放速率通过改变N-羟基磺酰胺衍生物上的功能基团的性质和位置来调节。
• N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS
  申请人：TOSCANO John P.

  公开号：US20120258965A1

  公开（公告）日：2012-10-11

  The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.

  本发明涉及一种在生理条件下捐赠亚硝基（HNO）的N-羟基磺酰胺衍生物，该衍生物在治疗和/或预防对亚硝基治疗有反应的疾病或病情的发生和/或发展方面具有用途，包括心力衰竭和缺血/再灌注损伤。新型的N-羟基磺酰胺衍生物在生理条件下以受控速率释放HNO，并且通过改变N-羟基磺酰胺衍生物上的功能基团的性质和位置来调节HNO释放的速率。
• NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION
  申请人：Cardioxyl Pharmaceuticals, Inc.

  公开号：EP2504003B1

  公开（公告）日：2016-11-09
• Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
  申请人：Mazhari Reza

  公开号：US20110160200A1

  公开（公告）日：2011-06-30

  The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof.
• US8227639B2
  申请人：——

  公开号：US8227639B2

  公开（公告）日：2012-07-24